Similarly, immunohistochemical staining indicated that the EGFR expression was significantly diminished in the tumor samples retrieved from the monensin treatment group, compared with that of the control group (Fig. 7C, panel c), consistent with the possibility that EGFR may be targeted by monensin in pancreatic cancer cells. The gene discussed is EGFR; the disease is pancreatic neoplasm.